Medeon Biodesign, Inc. (6499.TWO)
Taipei Exchange · TWD · Healthcare · Medical Instruments & Supplies
NT$78.60 (+1.81%) as of
Key statistics
- Market cap
- 7.62B
- Forward P/E
- 26.64
- EPS (TTM)
- -5.81
- Dividend yield
- 0.00%
- 52-week range
- 55.80 – 134.00
- Beta
- 0.62
- Revenue (TTM)
- 428.06M
- Profit margin
- -130.48%
- Analyst target
- NT$200.00
- Volume
- 67.70k
About Medeon Biodesign, Inc.
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site herniation caused by improper closure. It is engaged in the medical device contract manufacturing; and manufacture and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is based in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.